An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer

Inclusion Criteria:

• Measurable disease tumor available for biopsies
• Life expectancy of at least 3 months

Exclusion Criteria:

• Known or documented brain metastases prior to Cetuximab therapy